Investment Risk Analysis: Optceutics Limited (10015972)

1. Risk Rating: HIGH

The company is designated as being in "Liquidation" status, with deeply negative net assets of £80,874, shareholders' funds of minus £403,327, and virtually no cash reserves (£292). The solvency position is terminal and the business cannot meet its obligations as they fall due.

2. Key Concerns

a) Liquidation Status and Terminal Insolvency The most critical concern is the company's liquidation status. Net assets have deteriorated from £2,306 in 2023 to negative £80,874 in 2024, with shareholders' funds swinging from £322,444 to negative £403,327. This represents a catastrophic erosion of approximately £725,000 in equity within a single year. The company is balance-sheet insolvent by a significant margin.

b) Acute Liquidity Crisis Current assets of £3,393 are dwarfed by current liabilities of £83,390, yielding a current ratio of approximately 0.04:1. Cash has depleted from £21,590 to just £292. The company has virtually no liquidity to fund operations, pay creditors, or continue its research activities. Trade creditors have nearly doubled from £12,240 to £24,066, and "other creditors" have surged from £8,216 to £58,191 — a seven-fold increase that warrants scrutiny.

c) Overdue Confirmation Statement The confirmation statement is overdue (due 4 March 2026 per records, but flagged as overdue), suggesting governance and compliance are deteriorating alongside the financial position. This is particularly concerning when a company is already in liquidation proceedings.

3. Positive Indicators

a) Accounts Filed and Current Despite the liquidation status, the company filed accounts made up to 31 March 2024 (approved October 2024), which are not overdue. This provides recent visibility into the financial position.

b) Scientific Credibility of Board The directors include Professor Stephen James Brocchini and Dr Christopher Ross Redhead, suggesting meaningful scientific expertise relevant to the biotechnology focus (SIC 72110). The PK-Eye product described on the website indicates the company had developed a differentiated research tool for ophthalmic pharmacokinetics.

c) Historical Resilience Through Shareholder Support The accounts note that shareholders provided support via Unsecured Loan Notes, and the company has survived previous periods of negative net assets (2017-2019, 2021). This suggests a pattern of investor commitment, though whether this can continue under liquidation is doubtful.

4. Due Diligence Notes

a) Clarify Liquidation Status There is a discrepancy in the data: the status field shows "Liquidation" but the in_liquidation flag shows "False." It is essential to verify with Companies House whether formal liquidation proceedings have commenced, what type of liquidation (voluntary or compulsory), and when the process was initiated. This fundamentally affects any assessment.

b) Investigate "Other Creditors" Increase The jump in other creditors from £8,216 to £58,191 requires explanation. This could represent director loans called in, accrued liabilities, or provisions. Understanding the nature and priority of these claims is critical for assessing creditor recovery prospects.

c) Point Guard Partners LLC Commitment The PSC (Point Guard Partners LLC, a US entity owning 25-50%) should be investigated to understand their ongoing position, whether they are a source of the loan notes referenced in the going concern note, and what their intentions are regarding the liquidation process.

d) Intellectual Property and Asset Realisation With tangible fixed assets of only £3,377 (net book value) but historical cost of £46,494, the company's real value likely resides in intellectual property and the PK-Eye technology. Understanding whether this IP can be monetised or sold during liquidation is essential for creditor recovery assessment.

e) Director Loan Activity Note 10 discloses a director loan to Dr C R Redhead that was repaid during the year. Given the overall cash depletion, the timing and priority of this repayment relative to other creditors should be examined.